Marked inhibitory activity of masked aryloxy aminoacyl phosphoramidate derivatives of dideoxynucleoside analogues against visna virus infection

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 17, Issue 4, 1998, Pages 296-302

  Balzarini, Jan ^a   Cahard, Dominique ^b   Wedgwood, Orson ^b   Salgado, Antonio ^b   Velázquez, Sonsolez ^b   Yarnold, Christopher J ^b   De Clercq, Erik ^a   McGuigan, Christopher ^b   Thormar, Halldor ^c  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF ICELAND   (Iceland)

Author keywords

(Dideoxy)nucleoside analogues; AIDS; HIV; Masked aryloxyaminoacylphosphoramidate (dideoxy)nucleoside analogues; Reverse transcriptase; Visna virus

Indexed keywords

2',3' DIDEHYDRO 2',3' DIDEOXYADENOSINE; 2',3' DIDEOXYADENOSINE; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; STAVUDINE; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CHOROID; DRUG ACTIVATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; DRUG STABILITY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; SHEEP; STRUCTURE ACTIVITY RELATION; VISNA VIRUS;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; OVIS ARIES; VISNA VIRUS;

EID: 0031918981     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199804010-00002     Document Type: Article

References (27)

1. Balzarini J. Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives. Proceedings of the 4th Symposium of the European Society of Purine and Pyrimidine Metabolism in Man, Nijmegen, The Netherlands, August 30-September 3, 1993. Pharm World Sci 1994;16:113-26.
2. Balzarini J, De Clercq E. Biochemical pharmacology of nucleoside analogues active against HIV. In: Broder S, Merigan TC, Bolognesi D, eds. Textbook of AIDS medicine. Baltimore: Williams & Wilkins, 1994:751-72.
3. Sastry JK, Nehete PN, Khan S, et al. Membrane-permeable dideoxyuridine 5′-monophosphate analogue inhibits human immunodeficiency virus infection. Mol Pharmacol 1992;41:441-5.
4. Pompon A, Lefebvre I, Imbach J-L, Kahn S, Farquhar D. Decomposition pathways of the mono- and bis(pivaloyloxymethyl) esters of azidothymidine 5′-monophosphate in cell extract and in tissue culture medium: an application of the "on-line ISRP-cleaning" HPLC technique. Antiviral Chem Chemother 1994;5:91-8.
5. Valette G, Pompon A, Girardet J-L, et al. Decomposition pathways and in vitro HIV inhibitory effects of IsoddA pronucleotides: toward a rational approach for intracellular delivery of nucleoside 5′-monophosphates. J Med Chem 1996;39:1981-90.
6. Meier C, Lorey M, De Clercq E, Balzarini J. Cyclic saligenyl phosphotriesters of 2′,3′-dideoxy-2′,3′-didehydrothymidine (d4T) - a new pro-nucleotide approach. Bioorg Med Chem Lett 1997;7:99-104.
7. McGuigan C, Cahard D, Sheeka HM, De Clercq E, Balzarini J. Aryl phosphoramidate derivatives of d4T have improved anti-HIV efficacy in tissue culture and may act by the generation of a novel intracellular metabolite. J Med Chem 1996;39:1748-53.
8. Balzarini J, Karlsson A, Aquaro S, et al. Mechanism of anti-HIV action of masked alaninyl d4T-MP derivatives. Proc Natl Acad Sci USA 1996;93:7295-9.
9. Balzarini J, Wedgwood O, Kruining J, et al. Anti-HIV and anti-HBV activity and resistance profile of 2′,3′-dideoxy-3′-thiacytidine (3TC) and its arylphosphoramidate derivative Cf 1109. Biochem Biophys Res Commun 1996;225:363-9.
10. Balzarini J, Kruining J, Wedgwood O, et al. Conversion of 2′,3′-dideoxyadenosine (ddA) and 2′,3′-didehydro-2′,3′-dideoxyadenosine (d4A) to their corresponding aryloxyphosphoramidate derivatives markedly potentiates their activity against human immunodeficiency virus and hepatitis B virus. FEBS Lett 1997;410:324-8.
11. Balzarini J, Egberink H, Hartmann K, et al. Antiretrovirus specificity and intracellular metabolism of 2′,3′-didehydro-2′,3′-dideoxythymidine (stavudine) and its 5′-monophosphate triester prodrug So324. Mol Pharmacol 1996;50:1207-13.
12. Gangemi JD, Cozens RM, De Clercq E, Balzarini J, Hochkeppel H-K. 9-(2-Phosphonylmethoxyethyl)adenine in the treatment of murine acquired immunodeficiency disease and opportunistic herpes simplex virus infections. Antimicrob Agents Chemother 1989: 33:1864-8.
13. Balzarini J, Naesens L, Herdewijn P, et al. Marked in vivo antiretrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine, a selective anti-human immunodeficiency virus agent. Proc Natl Acad Sci USA 1989;86:332-6.
14. Naesens L, Balzarini J, De Clercq E. Single-dose administration of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) and 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP) in the prophylaxis of retrovirus infection in vivo. Antiviral Res 1991;16: 53-64.
15. Egberink H, Borst M, Niphuis H, et al. Suppression of feline immunodeficiency virus infection in vivo by 9-(2-phosphonomethoxyethyl)adenine. Proc Natl Acad Sci USA 1990; 87:3087-91.
16. Hartmann K, Balzarini J, Higgins J, De Clercq E, Pedersen NC. In vitro activity of acyclic nucleoside phosphonate derivatives against feline immunodeficiency virus in Crandell feline kidney cells and feline peripheral blood lymphocytes. Antiviral Chem Chemother 1994;5:13-9.
17. Balzarini J, Naesens L, Slachmuylders J, et al. 9-(2-Phosphonylmethoxyethyl)adenine (PMEA) effectively inhibits simian immunodeficiency virus (SIV) infection in rhesus monkeys. AIDS 1991;5:21-8.
18. Tsai CC, Follis KE, Sabo A, et al. Preexposure prophylaxis with 9-(2-phosphonylmethoxyethyl)adenine against simian immunodeficiency virus infection in macaques. J Infect Dis 1994;169:260-6.
19. Van Rompay KKA, Cherrington JM, Marthas ML, et al. 9-[2-(Phosphonomethoxy)-propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques. Antimicrob Agents Chemother 1996;40:2586-91.
20. Sonigo P, Alizon M, Staskus K, et al. Nucleotide sequence of the visna lentivirus: relationship to the AIDS virus. Cell 1985;42:369-82.
21. Gonda MA, Wong-Staal F, Gallo RC, Clements IE, Narayan O, Gilden RV. Sequence homology and morphologic similarity of HTLV-III and visna virus, a pathogenic lentivirus. Science 1985; 227:173-7.
22. Sigurdsson B, Pálsson PA, Grimsson H. J Neuropathol Exp Neurol 1957;16:389-403.
23. Gendelman HE, Narayan O, Kennedy-Stoskopf S, et al. Tropism of sheep lentiviruses for monocytes: susceptibility to infection and virus gene expression increase during maturation of monocytes to macrophages. J Virol 1986;58:67-74.
24. Georgsson G, Pálsson PA, Pétursson G. In: Racz P, Haase AT, Gluckman JC, eds. Modern pathology of AIDS and other retroviral infections: application of contemporary methods. Basel: Karger, 1990:82-98.
25. Thormar H, Balzarini J, Holý A, et al. Inhibition of visna virus replication by 2′,3′-dideoxynucleosides and acyclic nucleoside phosphonate analogues. Antimicrob Agents Chemother 1993;37: 2540-4.
26. Thormar H, Georgsson G, Pálsson PA, et al. Inhibitory effect of 9-(2-pbosphonylmethoxyethyl)adenine on visna virus infection in lambs: a model for in vivo testing of candidate anti-human immunodeficiency virus drugs. Proc Natl Acad Sci USA 1995;92: 3283-7.
27. Naesens L, Cahard D, Salgado A, et al. Metabolism and anti-HIV activity of phosphoramidate derivatives of D4T-MP with variations in the amino acid moiety. Proceedings of the 9th International/6th European Joint Symposium on Purine and Pyrimidine Metabolism in Man, Gmunden, Austria, 1-7 June 1997.